ERBB2 and neoplasm: Bertotti et al., conducted a multi-arm study in HER2-amplified patient-derived xenografts (PDXs) derived from mCRC patient samples and showed that simultaneous inhibition of HER2 and EGFR resulted in significant and sustained tumor regression [31].